AcuCort signs agreement with the CRO Quinta-Analytica concerning the performance of bioequivalence studies
AcuCort AB (AktieTorget: ACUC) today announces that the company has signed a collaboration agreement with the Czech CRO (Contract Research Organization) Quinta-Analytica s.r.o. concerning the performance of the bioequivalence studies that will form the basis for the applications for market approval for AcuCort’s drug candidate Dexa ODF in the EU and the US. Dexa ODF is a fast-dissolving oral film to be placed on the tongue for the treatment of acute allergic reactions.In order to apply for market approval in the EU and the US AcuCort needs to demonstrate bioequivalence between Dexa ODF and